New Delhi, September 18, 2025 – In a major crackdown on synthetic narcotics trafficking, the U.S. Embassy in New Delhi has revoked and denied visas for several Indian business executives and corporate leaders implicated in the illegal trade of fentanyl precursors. This action, part of the Trump Administration’s broader strategy to protect Americans from dangerous drugs, also extends to their close family members, rendering them ineligible for U.S. travel.

The decisions were made under sections 221(i), 212(a)(2)(C), and 214(b) of the Immigration and Nationality Act. The Embassy is additionally flagging executives linked to companies known for trafficking fentanyl precursors for enhanced scrutiny on future visa applications.

Chargé d’affaires Jorgan Andrews emphasized the U.S. commitment, stating, “The U.S. Embassy in New Delhi remains steadfast in its commitment to combating illicit drug trafficking. Individuals and organizations involved in the illegal production and trafficking of drugs to the United States, along with their families, will face consequences that may include being denied access to the United States.”

Curbing the influx of fentanyl and its precursors is a top priority for the U.S., with gratitude expressed to Indian counterparts for their collaboration in tackling this transnational threat. The Trump Administration has issued Executive Orders to secure borders, dismantle drug cartels, and urge reforms in source countries.

“Together, we will build a safer, healthier, stronger future for America and India,” the release concluded.